Chunlei Zhang

发表

Reproducibility analysis on shear wave elastography (SWE)-based quantitative assessment for skin elasticity

L. Cui, Shumin Wang, C. Ma, 2017, Medicine.

Improving precision of resection by pre‐surgery inspections with contrast‐enhanced ultrasound for dermatofibrosarcoma protuberans

L. Cui, C. Ma, Yang Sun, 2016, Dermatologic therapy.

Efficacy and safety of omalizumab in Chinese patients with anti‐histamine refractory chronic spontaneous urticaria

Jinhua Xu, R. Fogel, Jie Zheng, 2022, Dermatologic therapy.

A Multimodal Deep Learning-based Platform that Assists in the Classification of Lupus Subtypes and Differential Diagnosis Among Lupus and Other Similar Skin Diseases

Haoran Hu, Jianyun Lu, Q. Lu, 2021 .

Visit Adherence of Mild to Moderate Psoriasis Patients: A Mobile-Based Randomized Study

Gang Wang, Yuling Shi, Kun Chen, 2021, Patient preference and adherence.

Assessment of 5‐Aminolaevulinic Acid Photodynamic Therapy (ALA‐PDT) in Chinese patients with actinic keratosis: Correlation of dermoscopic features with histopathology

Hua Zhang, Chunlei Zhang, Qian Zhang, 2020, The Australasian journal of dermatology.

Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial.

Jianyun Lu, Furen Zhang, Q. Lu, 2023, Chinese Medical Journal.

Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled phase 4 trial

Wei Zhu, Q. Lu, Jinhua Huang, 2020, European Journal of Dermatology.

A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.

G. Wang, Furen Zhang, Q. Lu, 2022, International immunopharmacology.

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study

X. Xiao, Yuling Shi, Yangfeng Ding, 2023, Clinical and translational science.

A Multi-Center, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study Evaluating Efficacy and Safety of Vunakizumab in Patients with Moderate-to-Severe Plaque Psoriasis.

Q. Guo, Xinghua Gao, Jinhua Xu, 2022, Journal of American Academy of Dermatology.

A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.

G. Wang, Furen Zhang, Q. Lu, 2022, International immunopharmacology.

Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study

Ying Li, Chunlei Zhang, Yanhua Liang, 2024, Dermatology and therapy.

Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.

Chunlei Zhang, Yan Lu, Jinnan Li, 2024, Advances in therapy.